KVAC
Keen Vision Acquisition Corporation11.79
+0.00+0%
Dec 15, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
108.92MP/E (TTM)
-Basic EPS (TTM)
-0.28Dividend Yield
0%Recent Filings
8-K
New NVH merger LOI signed
Keen Vision Acquisition terminated its prior merger agreement with Medera and signed a binding LOI on February 26, 2026, for a replacement deal merging Novoheart Group (NVH) into Parent at US$100M enterprise value. Parties target a definitive agreement by April 10, with ≥US$10M available liquidity post-closing, capped expenses, and optional PIPE within nine months—adapting to biotech volatility. Final structure awaits due diligence. Deal expires in nine months.
8-K
SPAC extends deadline 3 months
Keen Vision Acquisition Corporation extended its business combination deadline by three months to April 27, 2026, after shareholders approved trust and charter amendments on January 22, 2026, with Sponsor funding the $120,000 deposit via a convertible promissory note. Despite 3,781,900 shares redeemed, it buys six more months to July 27, 2026. Clock ticks on.
8-K
Extended SPAC deadline to Jan 2026
Keen Vision Acquisition Corporation issued a $144,670.38 unsecured promissory note to its sponsor on December 19, 2025, depositing funds into the trust to extend the business combination deadline to January 27, 2026. The interest-free note matures at closing or converts to units at $10.00 each. Deadline looms.
8-K
SPAC extends deadline via sponsor note
Keen Vision Acquisition Corporation issued an unsecured promissory note for $144,670.38 to its sponsor on November 18, 2025, with funds deposited into the trust to extend its business combination deadline past December 27, 2025. The interest-free note matures at closing or terminates if no deal occurs; sponsor can convert it into private units at $10.00 each. Deadline bought. Risks liquidation if no target found.
10-Q
Q3 FY2025 results
Keen Vision swung to a Q3 net profit of $373,466 from Trust dividends, yet costs edged up to $248,480 from $505,662 y/y while income plunged 70% on a shrunken $56M Trust post-redemptions. Shareholder deficit widened to $6.4M amid $3.7M accretion charges, offset by nine-month net of $1.5M versus $6.6M prior. Cash dwindles to $15,880; related-party debt climbs to $2.2M extension note, due November 2025. Merger signed September 2024 with Medera at $622.6M valuation. Trust holds firm. No business yet. Liquidation looms if no deal.
AQUC
Aquaron Acquisition Corp.
12.10+0.00
BAYA
Bayview Acquisition Corp
11.63-0.01
FVN
Future Vision II Acquisition Co
10.54+0.00
IBAC
IB Acquisition Corp.
10.45+0.00
KACLF
Kairous Acquisition Corp.
1.00+0.00
QETA
Quetta Acquisition Corporation
11.20-0.05
TAVI
Tavia Acquisition Corp.
10.41+0.00
TDAC
Translational Development Acqui
10.42+0.00
VACH
Voyager Acquisition Corp
10.57+0.00
YOTA
Yotta Acquisition Corporation
2.00+0.00